| Ações em Circulação | 77,187,823 shares |
| Ações de Insider | 27,921,493 shares |
| Propriedade de Insider | 36.17 % |
| Total de Insiders | 49 |
Pontuação de Sentimento de Insider
A Pontuação de Sentimento de Insider encontra as empresas que estão sendo compradas por insiders corporativos.
É o resultado de um modelo quantitativo sofisticado e multifatorial que identifica empresas com os mais altos níveis de acumulação por insiders. O modelo de pontuação usa uma combinação do número líquido de insiders comprando nos últimos 90 dias, o total de ações compradas como um percentual do float, e o total de ações possuídas por insiders. A escala varia de 0 a 100, com números mais altos indicando um maior nível de acumulação em relação aos seus pares, e 50 sendo a média.
Frequência de Atualização: Diariamente
Pontuação de Sentimento dos Oficiais
A Pontuação de Sentimento de Officer encontra empresas que estão sendo compradas por Oficiais Corporativos.
Por definição, Oficiais Corporativos são Insiders Corporativos, mas, ao contrário de alguns outros Insiders (Acionistas de 10% e Membros do Conselho), os Oficiais trabalham para a empresa diariamente, e eles usam seu próprio dinheiro ao negociar. (Acionistas de 10% e Membros do Conselho muitas vezes são gestores de fundos que gerenciam o dinheiro de outras pessoas.) Como tal, as negociações de insiders feitas por Oficiais são muito mais significativas e devem ser tratadas apropriadamente.
Como a Pontuação de Sentimento dos Insiders, a Pontuação de Sentimento de Officer é o resultado de um modelo quantitativo sofisticado e multifatorial que identifica empresas com os mais altos níveis de acumulação por parte dos oficiais.
Frequência de Atualização: Diariamente
Principais Métricas de Insider
Este cartão mostra como a empresa se classifica em várias métricas internas. O percentil mostra como esta empresa se compara a outras empresas nos mercados dos EUA. Classificações mais altas são indicativas de situações melhores.
Por exemplo, geralmente aceita-se que a compra interna é um indicador positivo, portanto, empresas com mais compras internas teriam classificações mais altas do que empresas com menos compras internas (ou até mesmo venda interna).
Percentual do Float Comprado por Insiders (Classificação)
2568 out of 10786
Percentual do Float Comprado por Insiders é o número total de ações compradas por insiders menos o número total de ações vendidas por insiders nos últimos 90 dias, dividido pelo total flutuante e multiplicado por 100.
Gráfico de Negociação de Insider
Eledon Pharmaceuticals, Inc. negociações de insiders são mostradas no seguinte gráfico. Insiders são oficiais, diretores ou investidores significativos em uma empresa. Em geral, é geralmente ilegal para insiders realizarem negociações em suas empresas com base em informações materiais, não públicas. Isso não significa que seja ilegal para eles fazerem quaisquer negociações em suas próprias empresas. No entanto, eles devem relatar todas as negociações à SEC através de um Formulário 4.
Roster de Insider e Métricas de Lucratividade
Esta tabela mostra a lista de insiders conhecidos, e é gerada automaticamente a partir de arquivamentos divulgados à SEC. Além dos nomes, título mais recente, e designação de diretor, oficial ou proprietário de 10%, fornecemos as últimas participações divulgadas. Adicionalmente, quando possível fornecemos o desempenho comercial histórico do insider. O desempenho comercial histórico é uma média ponderada do desempenho de transações reais de compra no mercado aberto feitas pelo insider. Para mais informações sobre como isso é calculado, assista este webinar no YouTube.
See our leaderboard of most profitable insider traders.
| Insider | Lucro Médio (%) | Ações Possuídas |
Ajuste de Divisão |
|---|---|---|---|
|
Apple Tree Partners Ii Lp
Director, 10% Owner -
[D]
|
4,218,641 | 4,218,641 | |
|
Apple Tree Partners II - Annex, L.P.
Director, 10% Owner -
[D]
|
3,568,438 | 3,568,438 | |
|
Apple Tree Partners IV, L.P.
Director, 10% Owner -
[D]
|
250,000 | 250,000 | |
| Timothy J Barberich Director - [D] | 121,077 | 121,077 | |
| Biotechnology Value Fund Ii Lp - | 113,152 | 220,460 | |
| Biotechnology Value Fund L P - | 113,152 | 220,460 | |
|
Bvf Gp Holdings Llc
10% Owner -
|
113,152 | 220,460 | |
| Bvf I Gp Llc - | 113,152 | 220,460 | |
| Bvf Ii Gp Llc - | 113,152 | 220,460 | |
|
Bvf Inc/il
10% Owner -
|
113,152 | 220,460 | |
|
Bvf Partners L P/il
10% Owner -
|
220,460 | 220,460 | |
| BVF Partners OS Ltd. - | 113,152 | 220,460 | |
| Biotechnology Value Trading Fund OS LP - | 113,152 | 220,460 | |
| Buckley Stephen Jr. Director - [D] | 11,000 | 11,000 | |
| Erez Chimovits Director - [D] | 3,183,314 | 3,183,314 | |
| Cheryl Cohen Director - [D] | 0 | 0 |
| Insider | Lucro Médio (%) | Ações Possuídas |
Ajuste de Divisão |
|---|---|---|---|
| Flesher Gregory J. Chief Executive Officer, Director - [D] [O] | 156,918 | 156,918 | |
| Karen Jean Ferrante | 62,000 | ||
| David-Alexandre C Gros Chief Executive Officer, Director - [D] [O] | 9,000 | 9,000 | |
|
Seth Loring Harrison
Director, 10% Owner -
[D]
|
7,912,079 | 7,912,079 | |
| Jan Hillson Director - [D] | 3,430 | 3,430 | |
| Lee Kalowski Chief Financial Officer - [O] | 40,953 | 40,953 | |
| Keith Katkin Director - [D] | 8,575 | 8,575 | |
| Kessler David A. | 12,000 | ||
| Allan Kirk Director - [D] | 3,430 | 3,430 | |
| Jon Kuwahara See Remarks - [O] | 5,974 | 5,974 | |
|
Mark N Lampert
10% Owner -
|
113,152 | 220,460 | |
|
Lifesci Index Partners Llc
10% Owner -
|
1,065,867 | 1,065,867 | |
| Gary A Lyons Director - [D] | 0 | 0 | |
| June Lee Director - [D] | 3,430 | 3,430 | |
| Paul Sean Little CHIEF FINANCIAL OFFICER - [O] | 10,000 | 10,000 | |
|
Logos Global Management LP
10% Owner -
|
224,071 | 224,071 |
| Insider | Lucro Médio (%) | Ações Possuídas |
Ajuste de Divisão |
|---|---|---|---|
| McBride John S. Director - [D] | 3,430 | 3,430 | |
| Jodie Pope Morrison President and CEO, Director - [D] [O] | 57,566 | 57,566 | |
|
Ag Novartis
10% Owner -
|
4,493,458 | 4,493,458 | |
|
Bioventures Ltd Novartis
10% Owner -
|
4,493,458 | 4,493,458 | |
| Christine Ocampo See Remarks - [O] | 23,160 | 23,160 | |
| Walter C Ogier | 20,000 | ||
|
OrbiMed Israel BioFund GP Limited Partnership
Director, 10% Owner -
[D]
|
73,650 | 73,650 | |
|
OrbiMed Israel GP Ltd.
10% Owner -
|
73,650 | 73,650 | |
| Steven Perrin President, Director - [D] [O] | 1,000 | 1,000 | |
| Gerald E Quirk | 62,000 | ||
| Robinson James A. Jr. Director - [D] | 3,430 | 3,430 | |
|
Muneer A Satter
10% Owner -
|
1,771,688 | 1,771,688 | |
| Smith Bryan E. | 120,000 | ||
| Turkel Catherine C. President - [O] | 88,662 | 88,662 | |
|
Martin D Williams
10% Owner -
|
337,700 | 337,700 | |
|
Paul Yook
10% Owner -
|
1,065,867 | 1,065,867 | |
| Yanchik Joseph A., III Director - [D] | 51,092 | 51,092 |
Report errors via our new Insider Auditing Tool
Acompanhar Históricos de Compras de Insiders - Análise de Lucro a Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra de insider não planejada, feita no mercado aberto em ELDN / Eledon Pharmaceuticals, Inc.. Esta análise ajuda a entender se o insider gera consistentemente retornos anormais, e vale a pena ser seguido. Esta análise é para um ano após cada negociação, e os resultados são teóricos .
A tabela a seguir mostra as compras mais recentes no mercado aberto que não fizeram parte de um plano de negociação automática.
Preço Ajustado é o preço ajustado pelo desdobramento. Ações Ajustadas são as ações ajustadas pelo desdobramento.
Acompanhar Históricos de Vendas de Insiders - Análise de Perda a Curto Prazo
Nesta seção, analisamos a evitação de perda de curto prazo de cada venda de insider não planejada, feita no mercado aberto em ELDN / Eledon Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações de venda futuras possam prever quedas no preço. Esta análise é para um ano após cada negociação, e os resultados são teóricos .
A tabela a seguir mostra as vendas mais recentes no mercado aberto que não fizeram parte de um plano de negociação automática.
Preço Ajustado é o preço ajustado pelo desdobramento. Ações Ajustadas são as ações ajustadas pelo desdobramento.
Histórico de Transações
Clique no ícone de link para ver o histórico completo de transações. As transações relatadas como parte de um plano de negociação automática 10b5-1 terão um X na coluna marcada como 10b-5.
| Arquivo Data |
Data da Operação |
Formulário | Insider | Ticker | Título de Segurança | Código | Direto | Preço de Exercício Preço Unitário |
Preço por Unidade |
Unidades Alteradas |
Valor Alterado (1K) |
Opções Restantes |
Ações Restantes |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-16 | 2026-01-10 | 4 | Robinson James A. Jr. | ELDN | Common Stock | D | 3,430 | 3,430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Lee June | ELDN | Common Stock | D | 3,430 | 3,430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Katkin Keith | ELDN | Common Stock | D | 8,575 | 8,575 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Kirk Allan | ELDN | Common Stock | D | 3,430 | 3,430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Hillson Jan | ELDN | Common Stock | D | 3,430 | 3,430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | McBride John S. | ELDN | Common Stock | D | 3,430 | 3,430 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 75,431 | 220,460 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 821,121 | 2,633,679 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 1,031,385 | 3,361,803 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 86,341 | 145,029 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 837,146 | 1,812,558 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 1,055,445 | 2,330,418 | ||||||
| 2022-11-23 | 2022-11-23 | 4 | Perrin Steven | ELDN | Common Stock | D | 2.5969 | 1,000 | 3 | 1,000 | ||||
| 2022-02-02 | 2022-02-01 | 4 | Gros David-Alexandre C | ELDN | Stock Option (right to buy) | D | 3.97 | 108,000 | 108,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Smith Bryan E. | ELDN | Stock Option (right to buy) | D | 3.97 | 120,000 | 120,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Ogier Walter C | ELDN | Stock Option (right to buy) | D | 3.97 | 20,000 | 20,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Perrin Steven | ELDN | Stock Option (right to buy) | D | 3.97 | 155,000 | 155,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | McBride John S. | ELDN | Stock Option (right to buy) | D | 3.97 | 20,000 | 20,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | LYONS GARY A | ELDN | Stock Option (right to buy) | D | 3.97 | 20,000 | 20,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Lee June | ELDN | Stock Option (right to buy) | D | 3.97 | 20,000 | 20,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Hillson Jan | ELDN | Stock Option (right to buy) | D | 3.97 | 20,000 | 20,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Katkin Keith | ELDN | Stock Option (right to buy) | D | 3.97 | 20,000 | 20,000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Little Paul Sean | ELDN | Stock Option (right to buy) | D | 3.97 | 155,000 | 155,000 | |||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 975,412 | ||||||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 1,274,973 | ||||||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 58,688 | ||||||||
| 2021-12-21 | 2021-12-20 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 4.4800 | 2,000 | 9 | 9,000 | ||||
| 2021-08-19 | 2021-08-17 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 6.2100 | 4,000 | 25 | 7,000 | ||||
| 2021-06-14 | 2021-06-11 | 4 | Little Paul Sean | ELDN | Common Stock | D | 8.8700 | 10,000 | 89 | 10,000 | ||||
| 2021-06-10 | 2021-06-09 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 8.0100 | 3,000 | 24 | 3,000 | ||||
| 2021-05-04 | 2021-05-03 | 4 | Smith Bryan E. | ELDN | Stock Option (Right to Buy) | D | 9.91 | 158,500 | 158,500 | |||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -1,757 | 6,758 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -9,169 | 39,693 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -11,776 | 52,145 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -35 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -203 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -273 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 97,615 | 113,152 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 1,944 | 15,537 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 509,410 | 598,624 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 11,278 | 89,214 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 654,215 | 771,780 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 15,166 | 117,565 | ||||||
| 2020-12-04 | 2020-12-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 21.6000 | -103,200 | -2,229 | 73,650 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25.5507 | 9,098 | 232 | 224,071 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26.1740 | 15,000 | 393 | 214,973 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 27.0200 | -27 | -1 | 199,973 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25.8790 | 12,942 | 335 | 200,000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26.6442 | -12,942 | -345 | 187,058 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26.4824 | 15,000 | 397 | 200,000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25.9730 | 4,000 | 104 | 185,000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 24.5299 | 31,000 | 760 | 181,000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 24.0325 | 5,000 | 120 | 150,000 | ||||
| 2020-11-06 | 3 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 145,000 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 77,936 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 102,400 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 13,595 | ||||||||
| 2020-09-15 | 2020-09-11 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 500.00 | 1,167 | 1,167 | |||||
| 2020-09-15 | 2020-09-11 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 500.00 | 1,167 | 1,167 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 500.00 | 2,145 | 2,145 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 500.00 | 5,907 | 5,907 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Gros David-Alexandre C | NVUS | Stock Option (Right to Buy) | D | 500.00 | 18,278 | 18,278 | |||||
| 2020-03-20 | 2020-03-19 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 0.26 | 50,000 | 50,000 | |||||
| 2020-03-20 | 2020-03-19 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 0.26 | 100,000 | 100,000 | |||||
| 2020-03-20 | 2020-03-19 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 0.26 | 200,000 | 200,000 | |||||
| 2020-02-25 | 2020-01-14 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0.2000 | 646,204 | 129 | 0 | ||||
| 2020-02-25 | 2020-01-14 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0.2000 | 646,204 | 129 | 0 | ||||
| 2020-02-25 | 2020-01-14 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0.2000 | 646,204 | 129 | |||||
| 2020-02-25 | 2020-01-14 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0.2000 | 646,204 | 129 | |||||
| 2019-09-30 | 2019-09-26 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 0.67 | 100,000 | 100,000 | |||||
| 2019-09-30 | 2019-09-26 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 0.67 | 75,000 | 75,000 | |||||
| 2019-09-30 | 2019-09-26 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 0.67 | 60,000 | 60,000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Chimovits Erez | NVUS | Stock Option (Right to Buy) | D | 0.88 | 20,000 | 20,000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 0.88 | 20,000 | 20,000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 0.88 | 20,000 | 20,000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 0.88 | 20,000 | 20,000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 0.88 | 20,000 | 20,000 | |||||
| 2019-05-22 | 2019-05-21 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 1.9114 | -2,937 | -6 | 156,918 | ||||
| 2019-05-22 | 2019-05-20 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 1.9616 | -11,701 | -23 | 159,855 | ||||
| 2019-05-22 | 2019-05-21 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 1.9114 | -1,058 | -2 | 5,974 | ||||
| 2019-05-22 | 2019-05-20 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 1.9616 | -4,218 | -8 | 7,032 | ||||
| 2019-05-22 | 2019-05-21 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 1.9114 | -1,914 | -4 | 88,662 | ||||
| 2019-05-22 | 2019-05-20 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 1.9616 | -7,623 | -15 | 90,576 | ||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646,204 | 646,204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646,204 | 646,204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez | NVUS | Common Stock | I | 3.1000 | 646,204 | 2,003 | 3,183,314 | ||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646,204 | 646,204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646,204 | 646,204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 3.1000 | 646,204 | 2,003 | 3,183,314 | ||||
| 2019-05-02 | 2019-04-30 | 4 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, par value $0.01 per share | I | 2.7000 | -200 | -1 | 1,065,867 | ||||
| 2019-03-18 | 2019-03-14 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 3.72 | 25,000 | 25,000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 3.72 | 90,000 | 90,000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 25,000 | 171,556 | ||||||
| 2019-03-18 | 2019-03-14 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 3.72 | 50,000 | 50,000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 20,000 | 98,199 | ||||||
| 2018-09-13 | 2018-09-12 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 5.0190 | 16,632 | 83 | 78,199 | ||||
| 2018-09-13 | 2018-09-11 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 4.5560 | 17,048 | 78 | 61,567 | ||||
| 2018-09-07 | 2018-09-05 | 4 | TURKEL CATHERINE C. By Spouse's IRA | NVUS | Common Stock | I | 3.9660 | 805 | 3 | 805 | ||||
| 2018-06-14 | 2018-06-13 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 6.18 | 9,100 | 9,100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 6.18 | 9,100 | 9,100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 6.18 | 9,100 | 9,100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 6.18 | 9,100 | 9,100 | |||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2,132,134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2,132,134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2,132,134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2,132,134 | ||||||||
| 2018-03-15 | 2018-03-13 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 4.83 | 24,000 | 24,000 | |||||
| 2018-03-15 | 2018-03-13 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 20,000 | 44,519 | ||||||
| 2018-03-15 | 2018-03-13 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 4.83 | 56,500 | 56,500 | |||||
| 2018-03-15 | 2018-03-13 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 30,700 | 146,556 | ||||||
| 2018-03-15 | 2018-03-13 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 4.83 | 12,000 | 12,000 | |||||
| 2018-03-15 | 2018-03-13 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 11,250 | 11,250 | ||||||
| 2017-11-06 | 2017-11-06 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 4.21 | 50,000 | 50,000 | |||||
| 2017-07-10 | 2017-07-10 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 5.61 | 35,000 | 35,000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 5.85 | 36,000 | 36,000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Morrison Jodie Pope | NVUS | Stock Option (Right to Buy) | D | 5.85 | 18,000 | 18,000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 5.85 | 18,000 | 18,000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 5.85 | 18,000 | 18,000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 5.85 | 18,000 | 18,000 | |||||
| 2017-05-26 | 2017-05-24 | 4 | OCAMPO CHRISTINE | NVUS | Stock Option (Right to Buy) | D | 5.50 | 52,500 | 52,500 | |||||
| 2017-05-26 | 2017-05-24 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 5.50 | 52,500 | 52,500 | |||||
| 2017-05-26 | 2017-05-24 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 5.50 | 250,000 | 250,000 | |||||
| 2017-05-11 | 3 | LYONS GARY A | NVUS | No Securities Owned | D | 0 | ||||||||
| 2017-05-11 | 3 | FLESHER GREGORY J. | NVUS | Common Stock | D | 113,794 | ||||||||
| 2017-05-11 | 3 | FLESHER GREGORY J. | NVUS | Common Stock | D | 113,794 | ||||||||
| 2017-05-11 | 3 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 26,816 | ||||||||
| 2017-05-11 | 3 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 26,816 | ||||||||
| 2017-05-11 | 3 | Katkin Keith | NVUS | Common Stock | D | 24,238 | ||||||||
| 2017-05-11 | 3 | Katkin Keith | NVUS | Common Stock | D | 24,238 | ||||||||
| 2017-05-11 | 3 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 23,160 | ||||||||
| 2017-05-11 | 3 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 23,160 | ||||||||
| 2017-05-11 | 3 | Chimovits Erez By OrbiMed Israel GP Ltd. | NVUS | Common Stock | I | 5,074,220 | ||||||||
| 2017-05-11 | 3 | Chimovits Erez By OrbiMed Israel GP Ltd. | NVUS | Common Stock | I | 5,074,220 | ||||||||
| 2017-05-11 | 2017-05-10 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 9.9900 | 58,959 | 589 | 115,856 | ||||
| 2017-05-11 | 2017-05-10 | 4 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 9.9900 | 10,010 | 100 | 21,590 | ||||
| 2017-05-11 | 2017-05-10 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 9.9900 | 11,111 | 111 | 24,519 | ||||
| 2017-05-11 | 2017-05-09 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 2,537,110 | 2,537,110 | ||||||
| 2016-06-16 | 2016-06-15 | 4 | BARBERICH TIMOTHY J | TKAI | Stock Option (right to buy) | D | 6.29 | 12,000 | 12,000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Harrison Seth Loring | TKAI | Stock Option (right to buy) | D | 6.29 | 12,000 | 12,000 | |||||
| 2016-06-16 | 2016-06-16 | 4 | Cohen Cheryl | TKAI | Stock Option (right to buy) | D | 6.29 | 12,000 | 12,000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 6.29 | 12,000 | 12,000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Yanchik Joseph A., III | TKAI | Stock Option (right to buy) | D | 6.29 | 12,000 | 12,000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Kessler David A. | TKAI | Stock Option (right to buy) | D | 6.29 | 12,000 | 12,000 | |||||
| 2016-03-15 | 2016-03-15 | 4 | Buckley Stephen Jr. | TKAI | Common Stock | D | 5.7400 | 8,000 | 46 | 11,000 | ||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1.37 | -20,000 | 37,878 | |||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0.63 | -8,015 | 0 | |||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1.3700 | 20,000 | 27 | 57,566 | ||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0.6300 | 8,015 | 5 | 37,566 | ||||
| 2015-12-17 | 2015-12-15 | 4 | Ferrante Karen Jean | TKAI | Stock Option (right to buy) | D | 9.65 | 62,000 | 62,000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 9.65 | 189,000 | 189,000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Kalowski Lee | TKAI | Stock Option (right to buy) | D | 9.65 | 62,000 | 62,000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 9.65 | 62,000 | 62,000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Quirk Gerald E | TKAI | Stock Option (right to buy) | D | 9.65 | 62,000 | 62,000 | |||||
| 2015-11-12 | 2015-11-11 | 4 | Buckley Stephen Jr. | TKAI | Common Stock | D | 11.2500 | 3,000 | 34 | 3,000 | ||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4.19 | -13,500 | 186,678 | |||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Common Stock | D | 14.0100 | -13,500 | -189 | 0 | ||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Common Stock | D | 4.1900 | 13,500 | 57 | 13,500 | ||||
| 2015-09-08 | 2015-09-08 | 4 | Kalowski Lee | TKAI | Common Stock | D | 13.1300 | -4,668 | -61 | 40,953 | ||||
| 2015-09-04 | 2015-09-02 | 4 | Kalowski Lee | TKAI | Common Stock | D | 12.9600 | -2,158 | -28 | 45,621 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1.37 | -3,000 | 57,878 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0.63 | -7,000 | 8,015 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1.58 | -564 | 312,736 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1.3700 | 3,000 | 4 | 29,551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0.6300 | 7,000 | 4 | 26,551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13.7000 | -564 | -8 | 19,551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1.5800 | 564 | 1 | 20,115 | ||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1.58 | -12,000 | 313,300 | |||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13.7000 | -12,000 | -164 | 19,551 | ||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1.5800 | 12,000 | 19 | 31,551 | ||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0.63 | -7,426 | 15,015 | |||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 2.31 | -2,574 | 0 | |||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0.6300 | 7,426 | 5 | 19,551 | ||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 2.3100 | 2,574 | 6 | 12,125 | ||||
| 2015-07-17 | 2015-07-15 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.2580 | -3,566 | -51 | 4,493,458 | ||||
| 2015-07-15 | 2015-07-14 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.4100 | -27,861 | -401 | 4,497,024 | ||||
| 2015-07-15 | 2015-07-13 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.2020 | -20,611 | -293 | 4,524,885 | ||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1.58 | -8,000 | 325,300 | |||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13.7000 | -8,000 | -110 | 9,551 | ||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1.5800 | 8,000 | 13 | 17,551 | ||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1.58 | -8,000 | 333,300 | |||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13.8300 | -8,000 | -111 | 9,551 | ||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1.5800 | 8,000 | 13 | 17,551 | ||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4.19 | -300 | 200,178 | |||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Common Stock | D | 14.2000 | -300 | -4 | 0 | ||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Common Stock | D | 4.1900 | 300 | 1 | 300 | ||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4.19 | -6,700 | 200,478 | |||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Common Stock | D | 14.0000 | -6,700 | -94 | 0 | ||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Common Stock | D | 4.1900 | 6,700 | 28 | 6,700 | ||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4.19 | -2,000 | 207,178 | |||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Common Stock | D | 14.0200 | -2,000 | -28 | 0 | ||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Common Stock | D | 4.1900 | 2,000 | 8 | 2,000 | ||||
| 2015-06-19 | 2015-06-17 | 4 | BARBERICH TIMOTHY J | TKAI | Stock Option (right to buy) | D | 14.04 | 12,000 | 12,000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Harrison Seth Loring | TKAI | Stock Option (right to buy) | D | 14.04 | 12,000 | 12,000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 14.04 | 12,000 | 12,000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Yanchik Joseph A., III | TKAI | Stock Option (right to buy) | D | 14.04 | 12,000 | 12,000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Kessler David A. | TKAI | Stock Option (right to buy) | D | 14.04 | 12,000 | 12,000 | |||||
| 2015-06-18 | 2015-06-16 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.2700 | -1,120 | -16 | 4,545,496 | ||||
| 2015-06-16 | 2015-06-12 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.2000 | -5,919 | -84 | 4,561,393 | ||||
| 2015-06-16 | 2014-06-15 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.2000 | -14,777 | -210 | 4,546,616 | ||||
| 2015-06-12 | 2015-06-11 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.2000 | -27,875 | -396 | 4,567,312 | ||||
| 2015-05-28 | 2015-05-26 | 4 | Quirk Gerald E | TKAI | Stock Option (right to buy) | D | 10.81 | 214,605 | 214,605 | |||||
| 2015-04-20 | 2015-04-16 | 4 | Kalowski Lee | TKAI | Common Stock | D | 13.0000 | -4,567 | -59 | 47,779 | ||||
| 2015-04-13 | 3 | Cohen Cheryl | TKAI | No securities are beneficially owned | D | 0 | ||||||||
| 2015-04-13 | 2015-04-09 | 4 | Cohen Cheryl | TKAI | Stock Option (right to buy) | D | 11.08 | 25,000 | 25,000 | |||||
| 2015-04-06 | 2015-04-02 | 4 | Kalowski Lee | TKAI | Common Stock | D | 11.4500 | -2,258 | -26 | 52,346 | ||||
| 2015-03-20 | 2015-03-19 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.5000 | -46,141 | -669 | 4,595,187 | ||||
| 2015-03-20 | 2015-03-18 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14.5000 | -3,000 | -44 | 4,641,328 | ||||
| 2015-01-12 | 3 | Buckley Stephen Jr. | TKAI | No securities are beneficially owned | D | 0 | ||||||||
| 2015-01-12 | 2015-01-08 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 14.49 | 25,000 | 25,000 | |||||
| 2014-10-17 | 2014-10-15 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 13.25 | 134,134 | 134,134 | |||||
| 2014-10-17 | 2014-10-15 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 13.25 | 50,671 | 50,671 | |||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series E Preferred Stock | I | -8,013,003 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-3 Preferred Stock | I | -3,931,085 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-2 Preferred Stock | I | -457,728 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-1 Preferred Stock | I | -4,577,315 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Common Stock | I | 15.0000 | 150,000 | 2,250 | 1,771,688 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Common Stock | I | 1,621,688 | 1,621,688 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series E Preferred Stock | I | -24,199,308 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-3 Preferred Stock | I | -24,046,035 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-2 Preferred Stock | I | -1,539,643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-1 Preferred Stock | I | -8,711,335 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series C Preferred Stock | I | -14,604,833 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series B-2 Preferred Stock | I | -644,786 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series B-1 Preferred Stock | I | -798,067 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series A Preferred Stock | I | -4,500,000 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 15.0000 | 362,500 | 5,438 | 7,912,079 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 7,549,570 | 7,549,579 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Series E Preferred Stock | D | -24,199,308 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Series D-3 Preferred Stock | D | -10,675,613 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Common Stock | D | 15.0000 | 237,500 | 3,562 | 3,568,438 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Common Stock | D | 3,330,938 | 3,330,938 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1.58 | 165,251 | 165,251 | |||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series E Preferred Stock | D | -15,064,469 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-3 Preferred Stock | D | -13,222,826 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-2 Preferred Stock | D | -1,539,643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-1 Preferred Stock | D | -15,396,431 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 15.0000 | 325,000 | 4,875 | 4,644,328 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 4,319,328 | 4,319,328 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Series E Preferred Stock | D | -809,955 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Series D-3 Preferred Stock | D | -457,731 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Common Stock | D | 121,077 | 121,077 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-3 Preferred Stock | D | -13,370,422 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-2 Preferred Stock | D | -1,539,643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-1 Preferred Stock | D | -8,711,335 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series C Preferred Stock | D | -14,604,833 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series B-2 Preferred Stock | D | -644,786 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series B-1 Preferred Stock | D | -798,067 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series A Preferred Stock | D | -4,500,000 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 4,218,632 | 4,218,641 | ||||||
| 2014-09-24 | 3 | Apple Tree Partners IV, L.P. | TKAI | Common Stock | D | 250,000 | ||||||||
| 2014-09-24 | 3 | Apple Tree Partners IV, L.P. | TKAI | Common Stock | D | 250,000 | ||||||||
| 2014-09-18 | 2014-09-17 | 4 | Kalowski Lee | TKAI | Stock Option (right to buy) | D | 15.00 | 218,417 | 218,417 | |||||
| 2014-09-18 | 2014-09-17 | 4 | Kalowski Lee | TKAI | Common Stock | D | 54,604 | 54,604 | ||||||
| 2014-09-16 | 3 | Morrison Jodie Pope | TKAI | Common Stock | D | 19,102 | ||||||||
| 2014-09-16 | 3 | Morrison Jodie Pope | TKAI | Common Stock | D | 19,102 | ||||||||
| 2014-09-16 | 3 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 18 | ||||||||
| 2014-09-16 | 3 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 18 | ||||||||
| 2014-09-16 | 3 | Yanchik Joseph A., III | TKAI | Common Stock | D | 51,092 | ||||||||
| 2014-09-16 | 3 | Yanchik Joseph A., III | TKAI | Common Stock | D | 51,092 | ||||||||
| 2014-09-16 | 3 | Williams Martin D | TKAI | Common Stock | D | 337,700 | ||||||||
| 2014-09-16 | 3 | Williams Martin D | TKAI | Common Stock | D | 337,700 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 212,712 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring | TKAI | Common Stock | D | 425,397 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 212,712 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring | TKAI | Common Stock | D | 425,397 |
P
Compra de mercado aberto ou privada de ativo não-derivativo ou derivativo
S
Venda de mercado aberto ou privada de ativo não-derivativo ou derivativo
A
Concessão, premiação, ou outra aquisição de ativos da empresa (como uma opção)
C
Conversão de derivativo
D
Venda ou transferência de ativos de volta para a empresa
F
Pagamento do preço de exercício ou responsabilidade fiscal utilizando parte dos ativos recebidos da empresa
G
Doação de ativos pelo ou para o insider
K
Swaps de capital e transações de hedge similares
M
Exercício ou conversão de ativo derivativo recebido da empresa (como uma opção)
V
Uma transação voluntariamente reportada no Formulário 4
J
Outro (acompanhado de uma nota explicativa descrevendo a transação)
